An orthotopic transplantation mouse model experiment, with two types of human OSCC cell lines, showed that the administration of a TRKB-specific inhibitor significantly reduced tumor growth or invasion in HSC-3 (PD-OSCC, TRKBhigh/BDNFhigh)-derived tumors, but not in HSC-4 (WD-OSCC, TRKBlow/BDNFlow)-derived tumors. Here, NTRK2 is linked to neoplasm.